Want to see ARQT full AI Analyst Report?
ARQT Stock Chart & Stats
$24.53
-$0.25(-1.59%)
At close: 4:00 PM EST
$24.53
-$0.25(-1.59%)
Day’s Range― - ―
52-Week Range$13.70 - $31.77
Previous CloseN/A
Volume446.87K
Average Volume (3M)1.72M
Market Cap
$3.60B
Enterprise Value$3.26B
Total Cash (Recent Filing)$224.00M
Total Debt (Recent Filing)$114.67M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Jul 30, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding125,083,374
10 Day Avg. Volume1,603,455
30 Day Avg. Volume1,716,700
Financial Highlights & Ratios
PEG Ratio2.52
Price to Book (P/B)19.50
Price to Sales (P/S)9.82
P/FCF Ratio-585.47
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue7.84
Enterprise Value/Gross Profit8.62
Enterprise Value/Ebitda216.80
Forecast
1Y Price Target
$34.86Price Target Upside42.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.2
Revenue Forecast (FY)$497.10M
Bulls Say, Bears Say
Bulls Say
High Gross MarginA ~91% gross margin indicates durable product economics for Arcutis’ topical therapies. High gross margins create a structural cushion against rebates and SG&A investment, enabling scalable operating leverage as revenues expand and supporting sustainable cash generation as the franchise grows.
Strong Revenue And Share GainsRapid top-line growth and growing prescription share reflect durable commercial traction and improving formulary positioning. Consistent script momentum and share gains signal competitive advantage in branded non‑steroidal topicals, supporting long‑term revenue scalability as salesforce and channel access expand.
Positive Cash Flow And Low LeverageThe transition to positive operating and free cash flow, coupled with conservative leverage, materially improves financial flexibility. A stronger cash generation profile and low debt burden reduce refinancing risk, fund commercialization/pipeline investments, and increase resilience across business cycles.
Bears Say
High Gross-to-netSustained gross‑to‑net deductions in the 50% range materially reduce realized revenue and margin despite high gross margins. This structural rebate/discount pressure limits net pricing power, constrains cash conversion, and could persist as payers negotiate formulary positioning over the next several quarters.
Limited Medicare Part D AccessRestricted Part D coverage meaningfully narrows near‑term addressable market for older patients who often drive dermatology spend. Expanding Part D access is a multi‑plan, multi‑year process, delaying full commercial penetration and revenue upside from Medicare beneficiaries into 2027 and beyond.
Elevated SG&A And R&D SpendInvestments to expand the dermatology field force and advance pipeline increase recurring operating costs. While strategic for growth, elevated SG&A/R&D pressure margins and require sustained revenue acceleration to maintain profitability and FCF durability; any slowdown risks margin erosion.
Arcutis Biotherapeutics News
ARQT FAQ
What was Arcutis Biotherapeutics Inc’s price range in the past 12 months?
Arcutis Biotherapeutics Inc lowest stock price was $13.70 and its highest was $31.77 in the past 12 months.
What is Arcutis Biotherapeutics Inc’s market cap?
Arcutis Biotherapeutics Inc’s market cap is $3.60B.
When is Arcutis Biotherapeutics Inc’s upcoming earnings report date?
Arcutis Biotherapeutics Inc’s upcoming earnings report date is Jul 30, 2026 which is in 19 days.
How were Arcutis Biotherapeutics Inc’s earnings last quarter?
Arcutis Biotherapeutics Inc released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.064 by -$0.026.
Is Arcutis Biotherapeutics Inc overvalued?
According to Wall Street analysts Arcutis Biotherapeutics Inc’s price is currently Undervalued.
Does Arcutis Biotherapeutics Inc pay dividends?
Arcutis Biotherapeutics Inc does not currently pay dividends.
What is Arcutis Biotherapeutics Inc’s EPS estimate?
Arcutis Biotherapeutics Inc’s EPS estimate is 0.04.
How many shares outstanding does Arcutis Biotherapeutics Inc have?
Arcutis Biotherapeutics Inc has 125,083,374 shares outstanding.
What happened to Arcutis Biotherapeutics Inc’s price movement after its last earnings report?
Arcutis Biotherapeutics Inc reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.064. Following the earnings report the stock price went down -14.522%.
Which hedge fund is a major shareholder of Arcutis Biotherapeutics Inc?
Currently, no hedge funds are holding shares in ARQT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcutis Biotherapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.86 (42.10% Upside)
$34.86 (42.10% Upside)
Blogger Sentiment
Bullish
ARQT Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 481.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $157.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.5%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.39%
12-Months-Change
Fundamentals
Return on Equity
-1.41%
Trailing 12-Months
Asset Growth
33.68%
Trailing 12-Months
Company Description
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
ARQT Company Deck
ARQT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call described strong underlying commercial momentum and meaningful clinical and pipeline progress: 65% YoY revenue growth, share gains, positive operating cash flow, pediatric submissions, and initiation of ARQ-234 Phase I. These positives are tempered by a seasonality- and weather-driven Q1 demand dip (-6% QoQ for ZORYVE), continued material gross-to-net pressure (in the 50s), near-term SG&A/R&D increases, and limited Part D coverage today. Management emphasized that recent investments (sales force expansion, PCP/pediatric build, DTC) will drive demand in H2 2026 and a larger inflection in 2027, and they maintained full-year guidance of $480M–$495M.View all ARQT earnings summariesARQT Stock 12 Month Forecast
Average Price Target
$34.86
▲(42.10% Upside)
Technical Analysis
Travere Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Tarsus Pharmaceuticals
―
Recursion Pharmaceuticals
―
Ownership Overview
8.40% Insiders
16.09% Mutual Funds
0.41% Other Institutional Investors
61.07% Public Companies and
Individual Investors